Source comparison
CJC-1295 No DAC vs CJC-1295 DAC Dosing Comparison
Plasma Half-Life 28–32 minutes 6–8 days No DAC requires multiple daily doses; DAC requires once or twice weekly dosing Optimal Dose per Injection 100–200 mcg 500–2000 mcg No DAC uses fractional doses; DAC uses larger weekly bolus doses Dosing Frequency 1–3x da
This comparison does not assign a generated winner or score.
- Plasma Half-Life
- 28–32 minutes
- 6–8 days
- No DAC requires multiple daily doses; DAC requires once or twice weekly dosing
- Optimal Dose per Injection
- 100–200 mcg
- 500–2000 mcg
- No DAC uses fractional doses; DAC uses larger weekly bolus doses
- Dosing Frequency
- 1–3x daily
- 1–2x weekly
- No DAC mimics natural pulsatility; DAC creates sustained elevation
- GH Pulse Pattern
- Discrete pulses (90–120 min duration)
- Sustained elevation (blunted pulsatility)
- No DAC preserves circadian rhythm; DAC overrides it
- Risk of Desensitization
- Low (clears between pulses)
- Moderate to high (continuous receptor activation)
- No DAC allows receptor recovery; DAC may cause pituitary fatigue
- Professional Assessment
- Preferred for protocols requiring preserved pulsatility and circadian GH dynamics. Better long-term tolerability profile
- Preferred for protocols requiring constant GH elevation. Higher risk of negative feedback and receptor downregulation over weeks